All Pfizer articles – Page 3
-
BusinessPfizer gambles on $14bn Medivation deal
Cancer specialist likely just one target in hunt for marketed drugs to offset patent expiries
-
Business
US government sued over merger crackdown
Business groups challenge Obama’s steps to limit tax inversions
-
Business
Unpicking doctor payments
Accepting even small meals from drug industry reps appears to influence doctors’ prescription rates
-
News
US drug giant will no longer supply lethal injection drugs
With Pfizer’s exit no US-approved pharma firm will sell its drugs to be used in executions
-
Business
Pfizer to buy Anacor for eczema ointment
$5.2bn deal will bolster pharma giant’s inflammation and immunology drugs portfolio
-
Business
US treasury rules scupper Pfizer–Allergan merger
Government aims to crack down on corporate tax avoidance through ‘inversion’ deals
-
Business
Pfizer agrees potential $785m fraud settlement
Whistleblower case relates to claims of Wyeth overcharging for acid reflux drugs between 2001 and 2006
-
-
Business
BioAtla and Pfizer to collaborate on antibody research
Two-way agreement to share technology and royalties on new cancer drugs
-
-
Business
Heptares takes on new partners for drug discovery
Firm set to receive over $1bn from research partnerships
-
Business
Pfizer to close Cambridge pain outpost
120 jobs under threat from closure of Neusentis subsidiary R&D site
-
News
Pfizer’s response to compound fraud spotlights quality issues
‘Bosutinib isomer’ typifies threat posed by evolution of chemical supply chain
-
Business
Pfizer and Allergan agree mega-merger
$160 billion deal allows Pfizer to escape US tax system by re-homing in Ireland
-
Opinion
Human capital
Business leader: Incubators and hubs for small and medium-sized enterprises are all the fashion
-
Business
Merger fever sweeps pharma
The life sciences sector has been gripped by a mergers and acquisition frenzy, and it looks set to continue. But what does it mean for the industry?
-
Business
Cancer Drugs Fund axes 23 treatments
The UK government has cut down the list of cancer therapies it will pay for through the Cancer Drugs Fund
-
Business
Hospira buyout is a shot in the arm for Pfizer’s biosimilars
$17bn deal, intended to bolster sterile injectable and biologics capabilities, will be financed with existing cash and new debt
-
-
Business
Big pharma opens up abandoned drugs
Seven firms will make 68 stalled compounds available for academic research
